A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Completed · Phase 2
Conditions studied: Colorectal Cancer
In brief
The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
Key facts
- Study ID
- NCT00034619
- Run by
- Eli Lilly and Company
- Last updated by the study team
- 2006-07-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of primary cancer of the colon or rectum
- Must have measurable disease
- Must be able to comply with study procedure
You may not qualify if…
- Prior chemotherapy for advanced disease
- Pregnancy or lactation
- Candidates for surgical resection of one or more metastatic foci
- Second primary cancer
- Inability to take folic acid or vitamin B12
Where it is running
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Huntsville, Alabama, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Pittsfield, Massachusetts, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Kalamazoo, Michigan, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Latham, New York, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Asheville, North Carolina, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Goldsboro, North Carolina, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Hendersonville, North Carolina, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Winston-Salem, North Carolina, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Columbus, Ohio, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Bend, Oregon, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Portland, Oregon, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Philadelphia, Pennsylvania, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Pittsburgh, Pennsylvania, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Reading, Pennsylvania, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Charleston, South Carolina, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Ivins, Utah, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Ogden, Utah, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Provo, Utah, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — St. George, Utah, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Bellevue, Washington, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Seattle, Washington, United States
- "For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)" — Spokane, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.